Contract development and manufacturing organization (CDMO) Saneca Pharma has renewed an agreement with Pharmascience Inc., one of Canada’s largest pharmaceutical companies, for the manufacture and supply of prescription medicines in tablet form.
The agreement, which follows a successful GMP audit held in January 2018, includes the manufacture of 600 million enteric, chewable, and film-coated tablets (RX medicines) per year. It will also involve R&D and laboratory analyses related to existing and emerging formulations, as well as technical support in delivery to the Canadian market.
Pharmascience manufactures and markets prescription, over-the-counter, and behind-the-counter medicines, filling more than 45 million prescriptions each year in Canada. Based in Montreal, the company distributes its products across 60 countries worldwide.
Based in western Slovakia near Vienna, Saneca Pharma offers development and manufacturing capabilities for solids, semi-solids and liquids, as well as specialist services in tech-transfer, opiate APIs, and finished dosage forms.
The substantial agreement consists of nine different stock keeping units (SKUs), covering a number of therapeutic areas.
“Saneca Pharma is well located in Europe and its experience in manufacturing solid dose products was a huge part of the reason we selected them as our outsourcing partner for this project,” Pierre Plante, sourcing director at Pharmascience, said in a press statement.
(Source: Saneca Pharma)
